Report the Phase 2 readout for BIIB104 in cognitive impairment
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 May 2022
- Due
- 30 Jun 2022
- Delivered
- by 20 Jul 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Biogen expects the Phase 2 readout for BIIB104 in cognitive impairment associated with schizophrenia in mid-2022.”
What we found
Evidence strength A What the grades mean
The Phase 2 TALLY readout for BIIB104 was announced in July 2022, after the June 30, 2022 deadline. The results did not meet primary or secondary endpoints.
-
A Biogen 8-K filed 2022-07-20
“In July 2022 Biogen announced that the TALLY Phase 2 study of BIIB104 in cognitive impairment associated with schizophrenia did not meet its primary or secondary efficacy endpoints.” ✓ confirmed on the page
-
A Biogen 10-K filed 2023-02-15
“In July 2022 we announced that the Phase 2 TALLY study of BIIB104 in cognitive impairment associated with schizophrenia did not meet its primary or secondary efficacy endpoints.” ✓ confirmed on the page
Market reaction: the shares moved -7.1% against the S&P 500 over the three sessions around the disclosure (19 Jul 2022 to 22 Jul 2022). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 2 BIIB104 readout
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Biogen? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-BIIB-005351 · Corrections policy